Wall Street brokerages expect Gilead Sciences, Inc. (NASDAQ:GILD) to post earnings of $1.66 per share for the current quarter, according to Zacks. Nine analysts have issued estimates for Gilead Sciences’ earnings, with the lowest EPS estimate coming in at $1.57 and the highest estimate coming in at $1.83. Gilead Sciences reported earnings per share of $2.27 in the same quarter last year, which suggests a negative year-over-year growth rate of 26.9%. The business is scheduled to report its next quarterly earnings results after the market closes on Thursday, October 25th.

On average, analysts expect that Gilead Sciences will report full year earnings of $6.63 per share for the current financial year, with EPS estimates ranging from $6.35 to $7.06. For the next fiscal year, analysts expect that the company will post earnings of $6.58 per share, with EPS estimates ranging from $5.80 to $8.01. Zacks’ EPS averages are a mean average based on a survey of research firms that cover Gilead Sciences.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, July 25th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.56 by $0.35. The company had revenue of $5.65 billion for the quarter, compared to analyst estimates of $5.20 billion. Gilead Sciences had a return on equity of 41.57% and a net margin of 9.52%. The firm’s quarterly revenue was down 20.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.56 earnings per share.

A number of brokerages have issued reports on GILD. Wells Fargo & Co boosted their target price on Gilead Sciences from $89.00 to $95.00 and gave the company an “outperform” rating in a research report on Thursday, July 26th. Robert W. Baird lowered Gilead Sciences from an “outperform” rating to a “neutral” rating and set a $79.00 target price on the stock. in a research report on Thursday, July 26th. ValuEngine raised Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Friday, September 28th. BidaskClub raised Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, September 29th. Finally, Cantor Fitzgerald began coverage on Gilead Sciences in a research report on Monday, October 1st. They issued an “overweight” rating and a $87.00 target price on the stock. Eleven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $87.85.

Shares of NASDAQ GILD opened at $73.27 on Wednesday. The company has a market capitalization of $96.15 billion, a price-to-earnings ratio of 10.67, a PEG ratio of -3.77 and a beta of 1.01. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.92 and a current ratio of 3.00. Gilead Sciences has a 52-week low of $64.27 and a 52-week high of $89.54.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 27th. Stockholders of record on Friday, September 14th were given a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.11%. The ex-dividend date of this dividend was Thursday, September 13th. Gilead Sciences’s dividend payout ratio is currently 26.64%.

In other news, Director John C. Martin sold 50,000 shares of the company’s stock in a transaction on Tuesday, September 4th. The stock was sold at an average price of $74.16, for a total transaction of $3,708,000.00. Following the sale, the director now owns 3,067,762 shares of the company’s stock, valued at $227,505,229.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 150,000 shares of company stock worth $11,502,500 in the last ninety days. Corporate insiders own 1.30% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. West Coast Financial LLC grew its stake in shares of Gilead Sciences by 19.5% during the third quarter. West Coast Financial LLC now owns 6,395 shares of the biopharmaceutical company’s stock worth $494,000 after purchasing an additional 1,045 shares in the last quarter. NewSquare Capital LLC grew its stake in shares of Gilead Sciences by 9.2% during the third quarter. NewSquare Capital LLC now owns 19,978 shares of the biopharmaceutical company’s stock worth $1,543,000 after purchasing an additional 1,675 shares in the last quarter. Reilly Financial Advisors LLC grew its stake in shares of Gilead Sciences by 98.3% during the third quarter. Reilly Financial Advisors LLC now owns 1,420 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 704 shares in the last quarter. Cornerstone Wealth Management LLC grew its stake in shares of Gilead Sciences by 13.4% during the third quarter. Cornerstone Wealth Management LLC now owns 412,802 shares of the biopharmaceutical company’s stock worth $5,035,000 after purchasing an additional 48,753 shares in the last quarter. Finally, American Financial Network Advisory Services LLC grew its stake in shares of Gilead Sciences by 21,694.0% during the third quarter. American Financial Network Advisory Services LLC now owns 10,897 shares of the biopharmaceutical company’s stock worth $841,000 after purchasing an additional 10,847 shares in the last quarter. 78.06% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Featured Article: Discover Your Risk Tolerance

Get a free copy of the Zacks research report on Gilead Sciences (GILD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.